-
公开(公告)号:US20090304680A1
公开(公告)日:2009-12-10
申请号:US12463477
申请日:2009-05-11
IPC分类号: A61K39/395 , A61K31/711 , C12Q1/68 , C40B40/00 , C40B40/06 , G01N33/68 , C12Q1/02
CPC分类号: C12Q1/6883 , C12Q2600/118 , C12Q2600/136 , C12Q2600/156 , C12Q2600/172
摘要: A molecule for use in a method of treatment or diagnosis of Kawasaki Disease in an individual, the molecule comprising: (a) CACNA2D3; (b) CAMK2D; (c) KCNIP4; (d) ANGPT1; (e) NAALADL2; (f) ZFHX3; (g) MPHOSPH10; (h) a sequence having at least 90% sequence identity to any of (a) to (g); or (i) a modulator of any of (a) to (e). We also describe the use of Pregabalin ((3S)-3-(aminomethyl)-5-methyl-hexanoic acid) in the treatment or prevention of Kawasaki Disease in an individual.
摘要翻译: 一种用于个体治疗或诊断川崎病的方法的分子,所述分子包含:(a)CACNA2D3; (b)CAMK2D; (C)KCNIP4; (d)ANGPT1; (e)NAALADL2; (f)ZFHX3; (g)MPHOSPH10; (h)与(a)至(g)中任何一个具有至少90%序列同一性的序列; 或(i)(a)至(e)中任一项的调节剂。 我们还描述了普瑞巴林((3S)-3-(氨基甲基)-5-甲基 - 己酸)在治疗或预防个体中川崎病的用途。